Low-Dose Sublingual Ketamine for the Treatment of Raynaud's Phenomenon.
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A woman with primary Raynaud's phenomenon and treatment-resistant depression |
| Intervention | low-dose sublingual ketamine |
| Dose | low-dose |
| Topics | Esketamine Ketamine |
| Keywords | Anti-inflammatory drugs Cold sensitivity Low-dose ketamine Microvascular perfusion Numbness Peripheral vasodilation Raynaud's phenomena Skin color Skin texture Tingling Raynaud's syndrome Sublingual ketamine Vascular disorders |
| Key findings | Low-dose sublingual ketamine treatment for depression was associated with significant improvement in Raynaud's phenomenon symptoms. |
Abstract
Raynaud's phenomenon is a vascular disorder characterized by episodic vasospasm of small arteries, primarily affecting the hands and feet. Standard treatment strategies typically include lifestyle modifications to avoid cold exposure and stress, alongside pharmacological interventions aimed at increasing blood flow and reducing vascular constriction. Ketamine, an FDA-approved anesthetic since 1970, exhibits analgesic and vasodilatory properties that may enhance perfusion. This case report describes a woman with primary Raynaud's phenomenon whose symptoms improved significantly during treatment with low-dose sublingual ketamine prescribed for treatment-resistant depression. Further research into the use of this safe and inexpensive medicine as a treatment for Raynaud's phenomenon is recommended.